Clinical Trials

Thyroid eye disease is an autoimmune inflammatory disorder that can be vision-threatening and disfiguring.

New medical therapies are emerging to prevent and treat the disabling consequences of the disease.

We are involved in multiple clinical trials aimed at providing targeted therapy for TED.

What is TED?

Double Vision
Bulging Eyes
Redness & Swelling
Inability to close the eyes
Tearing & Irritation

Treatment costs are covered for patients who meet criteria for enrollment in Clinical Trials

This is a research study to evaluate how safe and effective VRDN-001 intravenous infusions are as a potential treatment for Thyroid Eye Disease. An infusion is delivering the study drug into a vein in your arm.

Inclusion Criteria

Age 18 years of age or older
Have clinical symptoms and signs of Thyroid Eye Disease
Both men and women need to avoid becoming pregnant during study screening up to and including 100 days after the last dose of study medication
Be willing and able to comply with all the requirements of the protocol for the entire duration of the study

Viridian Therapeutics, Inc is a biotechnology company advancing new treatments suffering Thyroid Eye Disease (TED) underserved by current therapies.

You will be compensated for your time and travel

Current Clinical Trials

Viridian (VRDN-001-302): NCT06179875

Viridian (VRDN-001-301): NCT05176639

Tourmaline (TOUR006-T01): NCT06088979

Immunovant (IMVT-1401-3201): NCT05517421

Horizon (HZNP-TEP-305): NCT06248619

Lassen (LASN01-CL-2201): NCT06226545

Our Team

Kimberly Cockerham, MD, FACS
Principal Investigator, Thyroid Eye Disease Clinical Trials
Neuro-ophthalmology, Oculofacial plastic Surgery & Orbital Oncology